MoonLake Immunotherapeutics (NASDAQ:MLTX) vs. Nuvation Bio (NYSE:NUVB) Head to Head Analysis

Nuvation Bio (NYSE:NUVB) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Nuvation Bio and MoonLake Immunotherapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1	1	9	1	2.83
MoonLake Immunotherapeutics	4	5	7	0	2.19

Nuvation Bio currently has a consensus target price of $10.40, suggesting a potential upside of 61.42%. MoonLake Immunotherapeutics has a consensus target price of $25.77, suggesting a potential upside of 57.37%. Given Nuvation Bio’s stronger consensus rating and higher probable upside, analysts plainly believe Nuvation Bio is more favorable than MoonLake Immunotherapeutics.

Earnings & Valuation

This table compares Nuvation Bio and MoonLake Immunotherapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$7.87 million	280.67	-$567.94 million	($0.64)	-10.07
MoonLake Immunotherapeutics	N/A	N/A	-$118.94 million	($3.32)	-4.93

MoonLake Immunotherapeutics has lower revenue, but higher earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nuvation Bio and MoonLake Immunotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-813.07%	-54.99%	-38.12%
MoonLake Immunotherapeutics	N/A	-55.57%	-45.18%

Volatility and Risk

Nuvation Bio has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500.

Insider and Institutional Ownership

61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 29.9% of Nuvation Bio shares are held by insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Nuvation Bio beats MoonLake Immunotherapeutics on 10 of the 14 factors compared between the two stocks.

About Nuvation Bio

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.